I don’t pretend to know the inside correlations needed to

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps ohm20 #103848
469
I don’t pretend to know the inside correlations needed to achieve half life or total receptor occupancy being attained or controlled for whatever length of time or dosage.

My thoughts as an average layman nobody and just as an investor is that Leronlimab needs to be used for a longer period to work. Our CD-12 trials showed us that it wasn’t enough length of time to fully activate the immune response. So it can help as an immune modulator and activate our immune system to work to destroy the virus. Maybe I am wrong about these thoughts but it just seems that the immune modulator part is the most important action for Covid. Turning the cells into positive cells allowing a full immune response to overcome the virus.

My comparison in my thoughts is to penicillin. We take the recommended dose and length of time and that you don’t stop the dosage and length of time but finish the whole prescription to allow penicillin to work. The doctor is usually adamant that you complete the whole prescription even if you feel better and have no signs of being sick anymore. My thoughts have always been that Leronlimab just needed more time to gain control of the micro environment. Maybe I am wrong on this but it is what I have thought since the end of the CD-12 trial showed us that we didn’t have enough time for long enough time period.

I am hoping this is true as I see it and that these Brazil Trials find for us the proper length of time needed and the right dosage for each indication. That we find out we are a life saving drug and the first ever to help Critical patients. A true lifesaving drug is what I would love to see.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Analyzing Fed's Policy Decision Amid Economic Fluctuations

Updated Category News Views 206

Understanding the Fed's Policy Decisions As we approach a crucial juncture for central bank policy, the upcoming decisions of the Federal Reserve are shaping up to be among the most complex and consequential in recent years. Economists and analysts hold differing views, strongly backed by a range of economic indicators and trends that suggest varying paths forward. The...

Continue Reading
Exploring the Growth Potential of Closed System Transfer Devices

Updated Category News Views 184

Overview of the Closed System Transfer Device Market The global closed system transfer device (CSTD) market is projected to experience significant growth in the coming years. Emerging technologies, evolving healthcare standards, and heightened awareness regarding occupational safety are positively influencing the market dynamics. The closed system transfer device market...

Continue Reading
Top High-Yield Dividend Stocks for Uncertain Markets Today

Updated Category News Views 96

Evaluating Safe Dividend Opportunities in Market Uncertainty In today's unpredictable market landscape, savvy investors are increasingly on the lookout for stocks that combine reliable income with growth potential. The need for stability is paramount as market conditions continue to fluctuate, pushing many to consider high-quality dividend-paying stocks that promise...

Continue Reading
AI Revolution: Job Risks and Investment Opportunities Ahead

Updated Category News Views 309

Geoffrey Hinton's Insights on AI's Impact on Employment Nobel laureate Geoffrey Hinton, recognized as the "Godfather of AI," has raised alarms about the growing trend of artificial intelligence (AI) leading to significant job losses. He asserts that tech companies are focusing on maximizing profits through the replacement of human labor with intelligent systems. This...

Continue Reading
Opportunities for Investors in PubMatic Securities Lawsuit

Updated Category News Views 165

Investors Unite in PubMatic Securities Fraud Action In recent developments, a number of investors in PubMatic, Inc. (NASDAQ: PUBM) have the chance to lead a class action lawsuit against the company due to alleged securities fraud. This opportunity arises as the deadline for filing a lead plaintiff motion approaches, signaling a crucial time for stakeholders. Understanding...

Continue Reading